Our Work in Rheumatology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Systemic Lupus Erythematosus, Vasculitis (GCA, PMR, ANCA), Gout
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with rheumatology related diseases and those who are close to them.
Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples – July 24, 2018
Rheumatologist User Base for Eli Lilly’s Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer’s Xeljanz Has Remained Flat Over the Past Quarter – July 17, 2018
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population – May 30, 2018
Warning to Eli Lilly’s Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat – May 10, 2018
ACR/ARHP Annual Meeting 2017